Squamous cervical cancer (which comprises 95% of all cervical cancers) is completely preventable if its precancerous stages of dysplasia, carcinoma in situ (now called cervical intraepithelial neoplasia), or microinvasive cancer are detected and treated. Detection is relatively simple and entails analysis of a sample of cells exfoliated within the ectocervix and endocervix. Exfoliative cytology, which is performed on nearly three million women in the United Kingdom each year, has unfortunately not reduced the number of deaths from cervical cancer as it has in other countries. ' The relative ineffectiveness of the screening programme in the United Kingdom seems to be related to two factors: the lack of an initial call system coupled with inadequacy of record and recall systems for women with abnormal findings and the fact that most smears are performed on relatively low risk young women. There has been a dramatic increase in the number of the precancerous lesions found, especially in young women, with an associated increase in deaths in this group, and this is imposing a great strain on the cytology screening system.2
What does an abnormal smear mean?
Abnormal conditions of the cervix identified in a smear can be divided into those which are definitely benign and those which are believed to have neoplastic potential. Benign abnormalities are relevant to the smear only if they prejudice its reliability as a test for the precancerous stages or if they are known to be associated with cervical intraepithelial neoplasia, as in the case of the human papillomavirus. BENIGN 
ABNORMALITIES

Inflammatory changes
Inflammatory changes are associated with cervicitis caused by Trichomonas vaginalis, candida, or other micro-organisms. They cause degenerative and regenerative changes in the epithelial cells, and some of the more severe changes approach the borderline with cervical intraepithelial neoplasia. Indeed, recent studies have shown that up to one fifth of recurrent inflammatory smears are associated with an underlying cervical intraepithelial neoplasia. Atrophic postmenopausal epithelium often shows severe inflammatory changes.
The cytopathic effects of the two main genital viruses-that is, herpes genitalis and human papillomavirus-are easily identified, the first by its multinucleate cell appearance and the second by the characteristic large perinuclear cavity or koilocyte and binucleation and hyperchromatism associated with keratinisation of the squamous cells. It is sometimes difficult for the cytologist to distinguish morphologically between cervical intraepithelial neoplasia and the effect of human papillomavirus with nuclear atypia. Indeed, about 83% of important squamous lesions have cytological evidence of infection with human papillomavirus. 3 
Unsatisfactory smear
In an unsatisfactory smear a diagnosis cannot usually be made because of too few cells, air drying of the cellular specimen, excess blood, the presence of large amounts of inflammatory debris, or the absence of endocervical cells. invasive cervical cancer, but this is not acceptable and the term neoplasia should be used for all preinvasive and invasive lesions and "malignancy" reserved for invasive disease.
Who should be screened? Controversy surrounds the question of who should be screened, which is particularly relevant in view of the dramatic increase in precancerous lesions in women under the age of 35. With limited resources the aim is to give efficient coverage to all women of all ages. With this in mind the DepartmenE of Health and Social Security has reconunended that "five year interval screening be performed on: women over 35 years of age (in whom 94% of deaths from cervical cancer occur) [and] women who have been pregnant on three or more occasions."4 The emphasis must be on recruiting women over 35 years of age who have never been screened; indeed, 92% of all women presenting with cancer fall into this group.
Screening younger women-that is, under the age of 35-also poses a problem. At present, 55% of all cytological tests originate from this age group. The DHSS has therefore suggested that "all women who have been sexually active should be screened at five yearly intervals but that unnecessary repeat smears in intervening years should not be taken. Also any women when first presenting for contraceptive advice should be smeared and thereafter at ages of20, 25, and 30."
Women who have been subjected to regular screening up to the age of 70 need not have smears after this age. Women presenting for the first time after the age of 70 or those who have symptoms of postmenopausal bleeding or a bloodstained discharge should, however, be clinically examined and have a smear taken; if necessary, referral should be arranged for dilatation and curettage.
Women at high risk of developing cervical carcinoma are: those who had their first pregnancy at an early age; those who have had three or more pregnancies; those with a history of sexually transmitted diseases, particularly genital warts, or multiple sexual partners; those whose male partner has genital warts; heavy smokers (more than 25 cigarettes a day); and women born around 1951, in whom there is a cohort group effect.
How often should women be screened?
Although the policy of five year screening seems rational considering present financial restraints, there are certain facts that may require it to be changed. Firstly, if, as seems likely, the present increase in the incidence of cervical dysplasia among young women continues throughout their lives, and ifsucceeding cohorts ofyoung women show similar increases, it will become imperative to increase the level of screening. Secondly, the presence of human papillomavirus in a cytological specimen indicates the need for surveillance at possibly yearly intervals because the virus is associated with the development of neoplasia in the lower genital tract.5 Thirdly, and probably most important, evidence shows that the degree of protection against cervical cancer given by a negative smear falls steadily after only three years.6 This last fact and data from other clinical studies suggest that the intervals between smears may need to be reduced below five years.7
Treatment
Cone biopsy, the removal of a segment of cervix under general anaesthesia, is both diagnostic and therapeutic. There are, however, both short term and long term complications, which invalidate its use in treating all precancerous lesions.! Local destructive techniques using cryotherapy, electrodiathermy under general anaesthesia, cold coagulation, or laser evaporation (probably the most versatile and effective) all give acceptable cure rates of 85-95% after one treatment. These methods are used to treat 80-85% of women presenting with abnormal smears in the United Kingdom; cone biopsy or hysterectomy (rarely) is used in the remainder.
Follow up of an abnormal smear
Many centres report that only up to 60% of women have satisfactory follow up and management after the first abnormal smear. Whatever the treatment given for an abnormal smear, the risk ofdeveloping subsequent invasive cancer still exists. A recently published study conducted over nearly 30 years found that women who continued to have abnormal smears after treatment had a risk of developing invasive cancer 25 times greater than normal; even those women who had normal smears after treatment had a risk 3-2 times greater than normal.9
These data indicate the need for lifelong cytological follow up.
Does the level ofatmospheric pressure affect the incidence ofthromboembolism?
The level of atmospheric pressure per se does not affect the incidence of thromboembolism. 
